Laboratorio Reig Jofre (XMAD:RJF) Cyclically Adjusted Revenue per Share: €4.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:RJF Laboratorio Reig Jofre SA XMAD:RJF
80 GF Score
Price €2.62
GF Value €2.72
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Laboratorio Reig Jofre Cyclically Adjusted Revenue per Share?

Laboratorio Reig Jofre XMAD:RJF 80 Cyclically Adjusted Revenue per Share is €4.13 as of Mar. 2026. GuruFocus rates XMAD:RJF with a GF Score™ of 80/100 and a GF Value™ of €2.72 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Laboratorio Reig Jofre's adjusted revenue per share for the three months ended in Mar. 2026 was €1.060. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Laboratorio Reig Jofre's average Cyclically Adjusted Revenue Growth Rate was 7.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Laboratorio Reig Jofre was 8.50% per year. The lowest was -0.50% per year. And the median was 3.30% per year.

As of today (2026-07-18), Laboratorio Reig Jofre's current stock price is €2.62. Laboratorio Reig Jofre's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €4.13. Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio of today is 0.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laboratorio Reig Jofre was 2.07. The lowest was 0.58. And the median was 0.75.


Laboratorio Reig Jofre  (XMAD:RJF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.62/4.13
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laboratorio Reig Jofre was 2.07. The lowest was 0.58. And the median was 0.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Laboratorio Reig Jofre Cyclically Adjusted Revenue per Share Related Terms


Laboratorio Reig Jofre Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Laboratorio Reig Jofre's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorio Reig Jofre Cyclically Adjusted Revenue per Share Chart

Laboratorio Reig Jofre Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.20 3.47 3.81 3.53 4.06

Laboratorio Reig Jofre Quarterly Data
Mar21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 3.89 3.90 4.06 4.13

XMAD:RJF vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorio Reig Jofre Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorio Reig Jofre's Cyclically Adjusted PS Ratio falls into.


XMAD:RJF
80GF Score
Laboratorio Reig Jofre SA XMAD:RJF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorio Reig Jofre Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorio Reig Jofre's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.06/129.8600*129.8600
=1.060

Current CPI (Mar. 2026) = 129.8600.

Laboratorio Reig Jofre Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.673 98.638 0.886
201606 0.651 100.333 0.843
201609 0.569 99.737 0.741
201612 0.666 101.842 0.849
201703 0.696 100.896 0.896
201706 0.642 101.848 0.819
201709 0.553 101.524 0.707
201712 0.758 102.975 0.956
201803 0.729 102.122 0.927
201806 0.683 104.165 0.851
201809 0.667 103.818 0.834
201812 0.728 104.193 0.907
201903 0.764 103.488 0.959
201906 0.575 104.612 0.714
201909 0.718 103.905 0.897
201912 0.702 105.015 0.868
202003 0.820 103.469 1.029
202006 0.711 104.254 0.886
202009 0.723 103.521 0.907
202012 0.783 104.456 0.973
202103 0.815 104.857 1.009
202106 0.708 107.102 0.858
202109 0.743 107.669 0.896
202112 0.822 111.298 0.959
202206 0.000 118.044 0.000
202209 0.808 117.221 0.895
202212 0.978 117.650 1.079
202303 1.014 118.948 1.107
202306 1.012 120.278 1.093
202309 1.032 121.343 1.104
202312 2.132 121.300 2.282
202403 1.097 122.762 1.160
202406 1.078 124.409 1.125
202409 1.003 123.121 1.058
202412 2.058 124.753 2.142
202503 1.098 125.531 1.136
202506 0.976 127.251 0.996
202509 0.917 126.840 0.939
202512 1.879 128.400 1.900
202603 1.060 129.860 1.060

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €4.13 mean?
Laboratorio Reig Jofre (XMAD:RJF) has a Cyclically Adjusted Revenue per Share of €4.13 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laboratorio Reig Jofre and its competitors.
Is Laboratorio Reig Jofre's Cyclically Adjusted Revenue per Share too high?
Laboratorio Reig Jofre's current Cyclically Adjusted Revenue per Share is €4.13. Overall, Laboratorio Reig Jofre has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Reig Jofre's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Laboratorio Reig Jofre's Cyclically Adjusted Revenue per Share of €4.13 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laboratorio Reig Jofre and its competitors. Laboratorio Reig Jofre's current Cyclically Adjusted Revenue per Share is €4.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Reig Jofre stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Reig Jofre (XMAD:RJF) is currently considered Fairly Valued. The stock's GF Value™ is €2.72, compared to a current price of €2.62 — trading 3.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €4.13. Laboratorio Reig Jofre's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Laboratorio Reig Jofre (XMAD:RJF), the current Cyclically Adjusted Revenue per Share is €4.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorio Reig Jofre (XMAD:RJF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorio Reig Jofre stock appears to be undervalued. The current stock price of €2.62 is trading 3.7% below its estimated GF Value™ of €2.72. GuruFocus considers Laboratorio Reig Jofre to be Fairly Valued.

Key valuation signals for XMAD:RJF:

  • Cyclically Adjusted Revenue per Share: €4.13
  • GF Value™: €2.72 vs. price of €2.62 (3.7% below fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the XMAD:RJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorio Reig Jofre Business Description

Other Exchanges 0RB1:UKFEQ1:Germany
Address Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
80GF Score

Get the complete analysis for XMAD:RJF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.62
Price
€2.72
GF Value